Lower back pain: stem cell and exosome infusion vs placebo
Official title: A Randomized, Placebo-Controlled, Single-Blind, Crossover Study to Evaluate the Safety and Preliminary Efficacy of a Single Intravenous AdiaVita (Umbilical Cord Blood - Stem Cells and Exosomes) Infusion in Adults With Chronic Mechanical Lower Back Pain
Run by Adia Med of Winter Park LLC · NCT07587047 · Data updated 2026-11-12
This study tests whether an umbilical cord blood–derived stem cell and exosome infusion can help adults with chronic degenerative lower back pain compared with placebo.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Adia Med of Winter Park LLC Academic / other |
| Locations | 1 site (Winter Park, Florida) |
| Status | Recruiting |
| Started | June 16, 2026 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07587047 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–85 with chronic (≥3 months) lower back pain and MRI-confirmed degenerative spine pathology who can consent and meet study cost requirements.
✕Probably not a fit
Participants who do not respond to the investigational infusion or experience adverse events may not see benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, single-blind, crossover trial evaluating the safety and potential efficacy of an intravenous infusion of investigational umbilical cord blood–derived stem cells and exosomes in adults with chronic mechanical lower back pain due to degenerative spine disease. About 100 participants aged 18–85 will receive either the stem cell infusion or placebo saline and then crossover to the other treatment after an initial period, with monitoring over six months. Primary focus is short-term safety, with exploratory endpoints including pain, disability, quality of life, MRI findings, and inflammatory biomarkers. Participants undergo MRI, laboratory tests, and regular follow-up visits to assess responses and any adverse events. The intervention is investigational and not FDA approved for this condition, and all participants will be followed for safety and efficacy signals during the study.
Why it matters
Potential benefit: If successful, participants may experience reductions in pain and improvements in function and quality of life.
How similar studies have gone: Prior studies in regenerative therapies for back pain have shown mixed or modest signals; this study explores a novel cell- and exosome-based approach with preliminary safety data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-85 years * Chronic lower back pain ≥3 months * MRI within 12 months demonstrating one or more qualifying diagnoses: Degenerative disc disease Disc bulge or herniation Modic changes Facet joint osteoarthritis Mixed disc and facet pathology * Baseline VAS-Average ≥4/10 * Able to comply with study visits and procedures * Able to provide written informed consent * Able to meet study cost requirements ($5,000 study fee plus MRI costs, if applicable) as described in the informed consent Exclusion Criteria: * Pregnancy or breastfeeding * Prisoners or decisionally impaired adults * Active malignancy (except non-melanoma skin cancer) * Immunodeficiency or active systemic infection * Prior lumbar surgery within 12 months * Epidural steroid or facet joint injection within 3 months * Participation in another interventional trial within 30 days * Known allergy to product components * Any medical condition posing unacceptable risk per investigator judgment. * Prior stem cell therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) at any time prior to screening
Where it's running
-
Adia Med Of Winter Park
Winter Park, Florida, United States Recruiting
Study contacts
- Principal investigator: Evan Thomas, MD, PhD — Adia Med of Winter Park LLC
- Study coordinator: Larry Powalisz
- Email: research@adiamed.com
- Phone: 3217880850
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Medical Massage Therapy for Subacute Lower Back Pain in Active-Duty Service Members
This study tests whether adding medical massage therapy to standard care can shorten duty-restriction periods and reduce pain for active-duty service members with subacute lower back pain.
-
Dynamic sitting with prototype office chairs for lower back pain
This study will test whether using two types of dynamic office chairs instead of a static chair can prevent or reduce lower back pain in office workers who tend to develop pain.
-
SPRINT peripheral nerve stimulation for chronic posterior sacroiliac joint (PSIJC) low back pain
This study will try a temporary SPRINT peripheral nerve stimulator to see if it reduces chronic PSIJC-related lower back pain in adults who have already tried physical therapy and medications.
-
Intrathecal CNTX-3001 for intractable chronic low back pain
This trial will test CNTX-3001, a non-opioid medicine given into the spinal fluid, to see if it is safe and helps adults with long-standing, treatment-resistant moderate to severe low back pain.
-
Three dry needling approaches for chronic low back pain
This study will see if three types of dry needling—dry needling alone, dry needling with high-rate PENS, and dry needling with low-rate PENS—reduce pain and improve quality of life for adults with chronic low back pain.
-
Robotic EMMA versus therapist-delivered lower back massage
This test compares a robotic device called EMMA to a certified massage therapist for adults with lower back pain to see if patient experience differs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.